Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVGBM dose-escalation and safety study after surgery for glioblastoma or astrocytoma
NL-OMON58764Phase 2Completed
- Sponsor
- CureVac
- Start
- Aug 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of CVGBM in glioblastoma (GBM) and astrocytoma, sponsored by CureVac. Primary endpoint: Primary endpoint(s). Started Aug 2023; status: completed.
02
Drugs
CVGBM
03
Conditions
glioblastoma (GBM)astrocytoma
Beyond the preview
Go deeper on NL-OMON58764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58764.